Safety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Phase 1

EmpagliflozinSafety, Tolerability, and Feasibility of Empagliflozin Therapy in Dialysis-dependent ESKD

Sponsor:

University of Utah

Code:

NCT05614115

Conditions

End-stage Kidney Disease

Kidney Disease, Chronic

Dialysis

Diabetic

Non-diabetic

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Empagliflozin

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by University of Utah on 2025-05-21.